Evidence map›Paper›PMID 28882290›Full record

ReviewJACC. Cardiovascular imaging2017

The Potential of Clinical Phenotyping of Heart Failure With Imaging Biomarkers for Guiding Therapies: A Focused Update.

Partho P Sengupta, Christopher M Kramer, Jagat Narula, Vasken Dilsizian

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JACC. Cardiovascular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06246188 (Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease Using Mobile Cardiac MRI Units in a Single-arm Open-label Study), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06246188 unknown statusnot on this mapstarted 2025, after this paper: background citation

Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease Using Mobile Cardiac MRI Units in a Single-arm Open-label Study

TypeobservationalSponsorGerman Heart InstituteRan2025 to 2025Enrolled80ConditionsCoronary Artery DiseaseArmsCardiac MRI using Regadenoson and GE-267
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Next-generation molecular imaging of cardiac fibrosis.The international journal of cardiovascular imaging · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Non-invasive imaging as the cornerstone of cardiovascular precision medicine.European heart journal. Cardiovascular Imaging · 2022
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Cardiovascular Precision Medicine in the Genomics Era.JACC. Basic to translational science · 2018
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Partho P SenguptaSection of Cardiology, West Virginia University Heart and Vascular Institute, West Virginia University, Morgantown, West Virginia. Electronic address: Partho.sengupta@wvumedicine.org.
Christopher M KramerDepartments of Medicine and Radiology and Cardiovascular Imaging Center, University of Virginia Health System, Charlottesville, Virginia.
Jagat NarulaZena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Vasken DilsizianDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
Cardiovascular Institute of the South · USUniversity of Maryland, Baltimore · USUniversity of Virginia Health System · USWest Virginia University · US

Funding

HCMR Novel Markers of Prognosis in Hypertrophic CardiomyopathyU01HL117006 · NHLBI · UNIVERSITY OF VIRGINIA · PI KRAMER, CHRISTOPHER M., NEUBAUER, STEFAN · 2013 to 2017
$14.5M
NHLBI NIH HHS U01 HL117006
6 · The paper itself

Abstract

The need for noninvasive assessment of cardiac volumes and ejection fraction (EF) ushered in the use of cardiac imaging techniques in heart failure (HF) trials that investigated the roles of pharmacological and device-based therapies. However, in contrast to HF with reduced EF (HFrEF), modern HF pharmacotherapy has not improved outcomes in HF with preserved EF (HFpEF), largely attributed to patient heterogeneity and incomplete understanding of pathophysiological insights underlying the clinical presentations of HFpEF. Modern cardiac imaging methods offer insights into many sets of changes in cardiac tissue structure and function that can precisely link cause with cardiac remodeling at organ and tissue levels to clinical presentations in HF. This has inspired investigators to seek a more comprehensive understanding of HF presentations using imaging techniques. This article summarizes the available evidence regarding the role of cardiac imaging in HF. Furthermore, we discuss the value of cardiac imaging techniques in identifying HF patient subtypes who share similar causes and mechanistic pathways that can be targeted using specific HF therapies.

Indexed as

Cardiac Imaging TechniquesBiomarkersClinical Decision-MakingFibrosisHeartHeart FailureHumansMolecular ImagingPatient SelectionPhenotypePredictive Value of TestsPrognosisSeverity of Illness IndexTissue SurvivalVentricular Function, LeftVentricular RemodelingBiomarkerscardiac imagingclinical trialsHFleft ventricular remodeling

Identifiers

PMID28882290
PMCPMC5612501
OpenAlexW2750836961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.